Major Trial Shows Promise for Non-Diabetic Kidney Disease

A phase III clinical trial has demonstrated that finerenone preserves kidney function and reduces cardiovascular events in patients with chronic kidney disease (CKD) who do not have diabetes, a population historically lacking effective treatment options.

The FIND-CKD study, presented at the European Renal Association Congress in Glasgow and published in the New England Journal of Medicine, enrolled over 1,500 patients with various causes of kidney damage. It stands as the largest phase III trial focused specifically on non-diabetic chronic kidney disease, making it particularly significant for Mexico, where CKD ranks among the leading causes of death and its non-diabetic form affects a substantial population.

Key Results

Clinical Impact

Professor Hiddo Lambers Heerspink of the University Medical Center Groningen called FIND-CKD "a large and rigorously conducted study" whose findings demonstrate that finerenone preserved kidney function and reduced the risk of adverse outcomes.

Manufactured by Bayer, the drug was already approved for kidney disease associated with type 2 diabetes. These new data potentially expand treatment access to millions of additional patients without the disease.

Chronic kidney disease progresses silently, and in advanced stages often requires dialysis or transplant, costly procedures that strain healthcare systems. The results pave the way for follow-up studies and discussions about new options for non-diabetic patients. Whether finerenone enters clinical practice guidelines will depend on regulatory review in each country, including Mexico.

Sources